Sánchez-Ramos Antonio, Galán-Ruano Ana, Vargas-Baquero Eduardo, Mas Manuel
Unidad de Sexualidad y Reproducción Asistida, Hospital Nacional de Parapléjicos, Toledo, España; Centro de Estudios Sexológicos (CESEX), Universidad de la Laguna, Tenerife, España; Fundación Lesionado Medular, Madrid, España.
Unidad de Sexualidad y Reproducción Asistida, Hospital Nacional de Parapléjicos, Toledo, España.
Rev Int Androl. 2018 Jul-Sep;16(3):95-101. doi: 10.1016/j.androl.2017.06.004. Epub 2017 Oct 11.
To assess the quality of sexual life reported by spinal cord-injured men treated with oral drugs for erectile dysfunction (ED) and their female partners.
Men with spinal cord injuries (SCI) complaining of ED and their female partners were evaluated using the Sexual Life Quality Questionnaire (SLQQ), a fully validated instrument in Spain. Two studies were conducted. A transversal study (1) on patients who were already on treatment with phosphodiesterase type 5 inhibitors (PDE5Is) and their partners, with 73 couples providing valid data. An additional prospective study (2) assessed SCI patients naive to PDE5Is in which both the patients and their spouses answered the SLQQ before treatment and after 3 months taking PDE5Is regularly, with 12 couples completing the study.
The SLQQ scores of SC injured men on PDE5Is (study 1) were under the remembered pre-lesion level, with lower scores reported by those with complete lesions (P<.2 vs incomplete). Their partners' SLQQ scores were apparently similar to pre-injury times. The SLQQ scores of the patients and their partners were well correlated (r = 0.57, P<.0001), and they both reported high treatment satisfaction. Study 2: Untreated SCI patients reported very low SLQQ scores that were improved by PDE5Is treatment (P<.004), albeit without reaching the pre-injury level. A similar trend was found in their partners. Again both patients and partners reported high treatment satisfaction scores (P <.001).
The sexual life quality levels of SC injured men on PDE5Is and their able-bodied spouses are well correlated. Both partners report high treatment satisfaction scores.
评估口服药物治疗勃起功能障碍（ED）的脊髓损伤男性及其女性伴侣报告的性生活质量。
使用《性生活质量问卷》（SLQQ）对主诉ED的脊髓损伤（SCI）男性及其女性伴侣进行评估，该问卷在西班牙已得到充分验证。进行了两项研究。一项横断面研究（1）针对已在使用5型磷酸二酯酶抑制剂（PDE5Is）治疗的患者及其伴侣，73对夫妇提供了有效数据。另一项前瞻性研究（2）评估了未使用过PDE5Is的SCI患者，患者及其配偶在治疗前和规律服用PDE5Is 3个月后均回答了SLQQ，12对夫妇完成了该研究。
使用PDE5Is的脊髓损伤男性的SLQQ评分（研究1）低于受伤前记忆水平，完全损伤者的评分更低（与不完全损伤者相比，P<0.2）。其伴侣的SLQQ评分明显与受伤前时期相似。患者及其伴侣的SLQQ评分相关性良好（r = 0.57，P<0.0001），他们均报告治疗满意度高。研究2：未治疗的SCI患者报告的SLQQ评分非常低，PDE5Is治疗使其有所改善（P<0.004），尽管未达到受伤前水平。在其伴侣中也发现了类似趋势。同样，患者和伴侣均报告治疗满意度评分高（P <0.001）。
使用PDE5Is的脊髓损伤男性及其健全配偶的性生活质量水平相关性良好。双方伴侣均报告治疗满意度高。
